Emcure Pharmaceuticals Limited has reshuffled its Board of Directors, appointing Raghu Kumar as an Additional Director (Non-Executive and Independent) effective August 06, 2026. The company’s Board approved the appointment on August 06, 2026, following a recommendation from the Nomination and Remuneration Committee. This move coincides with the departure of Chairman Berjis Desai, who will cease to hold office upon the conclusion of the ensuing Annual General Meeting (AGM) on September 21, 2026. Desai expressed unwillingness to seek re-appointment due to his new role as a member of the National Commission for Minorities in New Delhi. Consequently, Satish Mehta, the current Managing Director and CEO, will assume the role of Chairman from September 21, 2026.

The appointments were disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that Raghu Kumar is not debarred from holding director office by any SEBI order or exchange circulars, including BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/02, both dated June 20, 2018. Kumar is also unrelated to any existing Directors or Key Managerial Personnel of the company. His appointment as an Independent Director for a first term of three consecutive years is subject to shareholder approval at the AGM.

Key Board Changes

Raghu Kumar brings over four decades of experience in the pharmaceutical, healthcare, and consumer products sectors. He has held senior leadership positions at multinational organizations including Allergan, Novartis, and Bayer. Kumar currently serves as the Chairman and Independent Director of Emcutix Biopharmaceuticals Limited, a wholly-owned subsidiary of Emcure. He holds a Bachelor's Degree (Honours) in Economics and Mathematics from St. Stephen's College, University of Delhi, and a Post Graduate Degree in Business Management (Marketing) from the Indian Institute of Management, Ahmedabad.

Satish Mehta, who founded Emcure in 1981, continues to drive the company’s growth strategy. Under his leadership, Emcure has expanded its presence to more than 70 countries through subsidiaries in the UK, Canada, Singapore, Brazil, and other regions. The filing notes that Mehta is the father of Whole-time Directors Samit Mehta and Namita Thapar. The transition of the Chairman role to Mehta ensures continuity in leadership as the company maintains its focus on providing affordable, high-quality healthcare globally.

Emcure Pharmaceuticals delivered a robust start to FY27, with consolidated net profit after tax (PAT) surging 36.2% year-on-year to ₹2,925 million for the quarter ended June 30, 2026. The strong bottom-line performance was driven by a 22.8% revenue growth to ₹25,804 million and significant operating leverage that expanded EBITDA margins by 50 basis points. Alongside the financial results, the company announced key leadership transitions: Satish Mehta will assume the role of Chairman post-AGM, while Samit Mehta has been appointed Chief Operating Officer (COO) with oversight of R&D and operations.

The Board of Directors approved the unaudited results on August 6, 2026, under Regulation 30 of the SEBI Listing Regulations. The figures were reviewed by the Audit Committee and subjected to a limited review by statutory auditors B S R & Co. LLP, who issued an unqualified conclusion.

Financial Performance

Revenue from operations reached ₹25,804 million, up from ₹21,005 million in Q1FY26. EBITDA grew 25.8% to ₹5,080 million, with margins improving to 19.7% from 19.2% previously. While gross margins contracted by 340 basis points to 58.4% due to a higher mix of international sales, the company effectively managed fixed costs, leading to a 110 basis point expansion in PAT margin to 11.3%. Profit before tax (PBT) rose 35.3% to ₹3,935 million.

Segment Growth Drivers

International business accounted for 58% of total revenue, growing 34.2% to ₹14,851 million. The Rest of World (RoW) segment was the standout performer, surging 44.8% to ₹5,218 million, driven by robust anti-retroviral (ARV) order books. Europe revenue expanded 32.8% to ₹5,367 million, aided by Liposomal Amphotericin B contributions, while Canada grew 24.6% to ₹4,266 million. Domestic sales increased 10.2% to ₹10,953 million, supported by brands in CNS, cardiology, and women’s health, alongside normalized performance from Zuventus Healthcare.

Strategic & Operational Updates

Emcure completed its acquisition of the remaining minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary effective July 21, 2026. Samit Mehta will lead Gennova as CEO. In R&D, spending rose to ₹904 million (3.6% of revenue), reflecting investments in new candidates like SHetA2 (anti-HPV) and alimatravir (HIV PrEP). Capital expenditure stood at ₹1,168 million. Net debt increased to ₹11,026 million, resulting in a net debt-to-trailing twelve-month EBITDA ratio of 0.6x. Return on Capital Employed (RoCE) remained stable at 23.4%.

What the Numbers Show

The divergence between gross margin compression and EBITDA expansion underscores Emcure’s operational efficiency. Despite gross margins falling by 340 basis points due to the lower-margin international mix, EBITDA margins widened. This indicates that productivity gains and fixed-cost absorption outpaced top-line dilution. Furthermore, the sharp acceleration in RoW revenue (44.8%) versus domestic growth (10.2%) highlights the increasing reliance on international markets for volume growth, a trend supported by the expansion of the ARV portfolio through strategic licensing agreements.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE168P01015/5483f164-be5e-4dbe-a8a2-ac9d223cc805.pdf